Nachrichten zur GSK PLC LS-,3125 Aktie

SCYNEXIS jumps 92% on licensing deal with GSK for anti-fungal agent

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) and SCYNEXIS, Inc. (SCYX) announced Thursday they have entered into an exclusive licence…

BRIEF-GSK And Scynexis Announce An Exclusive Agreement To Commercialise & Develop Brexafemme To Treat Fungal Infection

...March 30 (Reuters) - GSK plc: * GSK - GSK AND SCYNEXIS ANNOUNCE......…

GSK agrees HIV deal that gives lower income nations access to drug

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK licenses companies to make cheap copies of HIV prevention drug

...By Maggie Fick LONDON (Reuters) - British drugmaker GSK has......…

J&J backs out of RSV vaccine race with rivals Pfizer and GSK

J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV…

Form 6-K GSK PLC For: Mar 28

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK says RUBY dostarlimab phase 3 trial shows positive results

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Jemperli cuts risk of death in uterus cancer patients subset by 72% but lower overall in trial

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Announces Positive Results From Phase III Trial Of Jemperli Combination In Endometrial Cancer

LONDON (dpa-AFX) - GSK PLC (GSK.L, GSK) announced positive results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating…

BRIEF-Gsk Says Jemperli Regulatory Submissions Planned For First Half Of 2023

...March 28 (Reuters) - GSK plc: * POSITIVE PHASE III RUBY RESULTS......…

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

GSK (GSK) closed at $35.04 in the latest trading session, marking a +1.92% move from the prior day....…

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recur

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…

GSK Endometrial Cancer Drug Jemperli Performs Well in Trial

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

BRIEF-GSK Says Regulatory Submissions For Jemperli (Dostarlimab) Plus Planned For The First Half Of 2023

...March 27 (Reuters) - GSK plc: * GSK - PHASE III RUBY CLINICAL TRIAL......…

Form 6-K GSK PLC For: Mar 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Glaxo loses bid to keep experts out of Zantac court showdown

The pharmaceuticals group and several rivals have been at the centre of a legal storm concerning the medicine, which was…

GSK, Haleon Stocks Drop After Setback on Zantac Cancer Litigation

Nearly four months after a federal court ruling eased investors' concerns, a decision by a state judge in California has…

Form 6-K GSK PLC For: Mar 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK falls after Zantac expert opinion ruling in California litigation

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK stock falls after California court ruling on Zantac; company disagrees with decision

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Disagrees With Ruling By California State Court

LONDON (dpa-AFX) - GSK PLC (GSK.L, GSK) issued a statement as response to Sargon ruling by the California state court…

GSK disagrees with California court ruling on Zantac litigation, shares down 4%

...(Reuters) - GSK Plc said on Friday it "respectfully disagrees......…

GSK Disagrees With Court Ruling to Allow Plaintiff-Expert Testimony in Goetz Case

GSK Disagrees With Court Ruling to Allow Plaintiff-Expert Testimony in Goetz Case...…

UPDATE 1-GSK disagrees with California court ruling on Zantac litigation, shares down 4%

...(Adds shares down) March 24 (Reuters) - GSK Plc said on Friday......…

GSK says it disagrees with California state court ruling on Zantac

U.K. pharmaceutical giant GSK on Friday said it disagreed with a California state court ruling on Zantac, or ranitidine, and…

BRIEF-GSK Says It Disagrees With Sargon Ruling By California State Court In Respect Of Goetz Case

...March 24 (Reuters) - GSK plc: * GSK PLC - STATEMENT: ZANTAC......…

GSK (GSK) Gains But Lags Market: What You Should Know

In the latest trading session, GSK (GSK) closed at $35.05, marking a +0.34% move from the previous day....…

Form 6-K GSK PLC For: Mar 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K GSK PLC For: Mar 20

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Here’s the GSK dividend forecast for 2023 and 2024

Roland Head looks at the latest GSK dividend forecasts and explains why hed consider buying the stock today, despite certain…

Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

An approved RSV vaccine could be the next big thing for these companies....…

ANALYSE-FLASH: Deutsche Bank Research hebt GSK auf 'Buy' und Ziel auf 1700 Pence

FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research hat GSK von "Hold" auf "Buy" hochgestuft und…

GSK rises as Deutsche upgrades to buy with 1700p target

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

How GSK plans to replenish its depleted medicine cabinet

...By Maggie Fick STEVENAGE, England (Reuters) - GSKs chief... August. But in an interview with Reuters he…

FOCUS-How GSK plans to replenish its depleted medicine cabinet

...-analysts By Maggie Fick STEVENAGE, England, March 15 (Reuters) - GSKs... last August. But in an interview with Reuters he said he had…

GSK (GSK) Gains But Lags Market: What You Should Know

GSK (GSK) closed the most recent trading day at $33.72, moving +0.6% from the previous trading session....…

ADRs End Higher; Credit Suisse, GSK Trade Actively

ADRs End Higher; Credit Suisse, GSK Trade Actively...…

With positive combo meningococcal vaccine data, GSK eyes US approval

...LONDON (Reuters) - GSK on Tuesday said that late-stage data......…

GSK Hold

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK auf "Hold" mit einem Kursziel von 1500…

Form 6-K GSK PLC For: Mar 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK lauds trial findings; asthma drug backed for review in China

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Nucala for severe asthma gets review in China

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK: China prüft Zulassung von Nucala bei Form von schwerem Asthma

Von Joe Hoppe LONDON (Dow Jones)--Der britische Pharmakonzern GSK hat für seine ergänzende Erhaltungstherapie Nucala in China die Zulassung…

GSK meldet Studienerfolg mit Meningokokken-Impfstoffkandidat

Von Michael Susin LONDON (Dow Jones)--Der britische Pharmakonzern GSK hat eine klinische Studie mit seinem Impfstoffkandidaten gegen die Bakterien,…

GSK Announces Positive Phase III Data For 5-in-1 Meningococcal ABCWY Vaccine Candidate

LONDON (dpa-AFX) - GSK plc. (GSK.L, GSK) announced positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate. MenABCWY…

GSK: China Accepts Regulatory Submission For Nucala In Severe Eosinophilic Asthma

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) said Tuesday that the China National Medical Products Administration has accepted for review…

GSK scores phase III success with meningococcal disease vaccine

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Reports Positive Phase 3 Data For Meningococcal Vaccine Candidate

GSK Reports Positive Phase 3 Data For Meningococcal Vaccine Candidate...…

BRIEF-GSK Says Positive Phase III Results For Menabcwy Vaccine

...March 14 (Reuters) - GSK plc: * GSK PLC - POSITIVE PHASE III RESULTS......…